Description: Azenta (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. In addition, the company operates the Semiconductor Solutions Group business, an industry-leading provider of semiconductor manufacturing automation and collaborative robotics solutions worldwide. On September 20, 2021, the Company announced the pending sale of this business to Thomas H. Lee Partners. Due to the pending divestiture, the Company began reporting the Semiconductor Solutions Group business as discontinued operations in its recent fiscal year-end earnings announcement. Azenta is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia.
Home Page: www.azenta.com
AZTA Technical Analysis
15 Elizabeth Drive
Chelmsford,
MA
01824
United States
Phone:
978 262 2626
Officers
| Name | Title |
|---|---|
| Dr. Stephen S. Schwartz | CEO, Pres & Director |
| Mr. Lindon G. Robertson | Exec. VP & CFO |
| Mr. Robin Vacha | Sr. VP of Global Operations |
| Mr. Michael Paulo | VP and Chief Information & Digital Officer |
| Sara Silverman | Head of Investor Relations |
| Mr. Jason W. Joseph | Sr. VP, Gen. Counsel & Corp. Sec. |
| Mr. John E. O'Brien | Sr. VP of Corp. Devel. |
| Ms. Claribel Purcell | Sr. VP of Global Sales |
| Ms. Kimberly Crowley | Sr. VP & Chief HR Officer |
| Mr. J. Robert Woodward | Sr. VP of Global Quality & Regulatory |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 28.9017 |
|---|---|
| Trailing PE: | 2.0439 |
| Price-to-Book MRQ: | 1.3459 |
| Price-to-Sales TTM: | 8.3272 |
| IPO Date: | 1995-02-02 |
| Fiscal Year End: | September |
| Full Time Employees: | 3200 |